Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

R-mini-CHOP preserves efficacy and limits toxicity for patients ≥ 80 years old with DLBCL

View Full Paper
Ask AI
Bookmark
Share

Authors

EHEric HansenPBPaul M. Barr

Discussion

Loading...

Member takes

Overview

Retrospective study finds R-mini-CHOP maintains efficacy in patients ≥ 80 with DLBCL, suggesting lower toxicity and discontinuation rates.

Key Points

  • To assess treatment patterns and outcomes of patients aged ≥ 80 diagnosed with DLBCL receiving first-line therapy.
  • Retrospective observational study using COTA real-world database from U.S. healthcare centers.
  • Included patients aged ≥ 80 diagnosed with DLBCL between 2011 and 2024 who initiated 1L therapy.
  • Analyzed patient characteristics and treatment patterns by regimens: R-CHOP/R-EPOCH, R-mini-CHOP, and Other Frail Regimens.
  • R-mini-CHOP had lower treatment discontinuation rates due to toxicity compared to R-CHOP/R-EPOCH.
  • Long-term outcomes were similar for R-mini-CHOP and R-CHOP/R-EPOCH, but worse for Other Frail Regimens.
  • Median rwPFS was 28.5 months for R-mini-CHOP compared to 34.0 months for R-CHOP/R-EPOCH.

Cite This Study

Hansen et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e05ahttps://doi.org/10.1182/blood-2025-6277
View Full Paper
Ask AI
Bookmark
Share